Publications by authors named "Daria Stroukova"
Article Synopsis
- The study investigates the safety and effectiveness of a new vaccine, MVA-BN-WEV, designed to protect against three encephalitic alphaviruses (WEEV, EEEV, VEEV) in healthy adults.
- Forty-five participants were given two doses of the vaccine at varying strengths, monitored for side effects and immune response over six months.
- Results showed the vaccine was generally safe with mild side effects, and it successfully triggered strong immune responses against all three viruses, especially at higher doses.
Background: Respiratory syncytial virus (RSV) causes significant disease burden in older adults. MVA-BN-RSV is a novel poxvirus-vectored vaccine encoding internal and external RSV proteins.
Methods: In a phase 2a randomized double-blind, placebo-controlled trial, healthy participants aged 18 to 50 years received MVA-BN-RSV or placebo, then were challenged 4 weeks later with RSV-A Memphis 37b.
Background: Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in young children and the elderly. Protective immunity is not generated after repeated infections, but vaccination may hopefully prove effective.
Methods: This phase 2 clinical study investigated a multivalent RSV vaccine (MVA-BN-RSV) designed to induce broad antibody and cellular immune responses by encoding RSV surface proteins F, G (for both A and B subtypes), and internal antigens (M2, N).
Respiratory disease caused by RSV infection is recognized as a severe public health issue in infants, young children and elderly with no specific treatment option. Vaccination may be the most effective strategy to combat this highly infectious virus although no vaccine has been approved. The novel vaccine candidate MVA-BN-RSV encodes RSV surface proteins F and G (subtypes A, B) as well as internal proteins N and M2 in the MVA-BN viral vector backbone to provide broad protection against RSV.
View Article and Find Full Text PDF